What is the official website of GENESIS Pharma ?

The official website of GENESIS Pharma is https://www.genesispharma.com.

What is GENESIS Pharma's cybersecurity risk score?

GENESIS Pharma has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has GENESIS Pharma experienced?

According to Rankiteo, GENESIS Pharma currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has GENESIS Pharma been affected by any supply chain cyber incidents ?

According to Rankiteo, GENESIS Pharma has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does GENESIS Pharma have SOC 2 Type 1 certification ?

According to Rankiteo, GENESIS Pharma is not certified under SOC 2 Type 1.

Does GENESIS Pharma have SOC 2 Type 2 certification ?

According to Rankiteo, GENESIS Pharma does not hold a SOC 2 Type 2 certification.

Does GENESIS Pharma comply with GDPR ?

According to Rankiteo, GENESIS Pharma is not listed as GDPR compliant.

Does GENESIS Pharma have PCI DSS certification ?

According to Rankiteo, GENESIS Pharma does not currently maintain PCI DSS compliance.

Does GENESIS Pharma comply with HIPAA ?

According to Rankiteo, GENESIS Pharma is not compliant with HIPAA regulations.

Does GENESIS Pharma have ISO 27001 certification ?

According to Rankiteo,GENESIS Pharma is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does GENESIS Pharma operate in ?

GENESIS Pharma operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does GENESIS Pharma have ?

GENESIS Pharma employs approximately 193 people worldwide.

Does GENESIS Pharma own any subsidiaries ?

GENESIS Pharma presently has no subsidiaries across any sectors.

How many LinkedIn followers does GENESIS Pharma have ?

GENESIS Pharma's official LinkedIn profile has approximately 14,585 followers.

What is the NAICS classification code for GENESIS Pharma ?

GENESIS Pharma is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does GENESIS Pharma have a Crunchbase profile ?

No, GENESIS Pharma does not have a profile on Crunchbase.

Does GENESIS Pharma have a LinkedIn profile ?

Yes, GENESIS Pharma maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/genesis-pharma.

How many cybersecurity incidents has GENESIS Pharma experienced ?

As of October 17, 2026, Rankiteo reports that GENESIS Pharma has not experienced any cybersecurity incidents.

How many peer or competitor companies does GENESIS Pharma have ?

GENESIS Pharma has an estimated 5,773 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

GENESIS Pharma

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

GENESIS Pharma Vendor Cyber Rating & Cyber Score

genesispharma.com

Add Your Compliance Badge

GENESIS Pharma is a biopharmaceutical company specializing in the commercialization of innovative pharmaceutical products for serious and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was the first pharmaceutical company in Greece and one of the first in Europe to focus on the sales, marketing and distribution of biopharmaceutical products. Shortly after its founding, the company began to steadily expand at a regional level, today covering most countries in the CEE region. The robust network of its strategic partnerships comprises leading international pharmaceutical companies dedicated to cutting-edge R&D, alongside fast-growing biopharmaceutical companies with pioneering research and disruptive

GENESIS Pharma

GENESIS Pharma CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

GENESIS Pharma Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for GENESIS Pharma

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for GENESIS Pharma in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for GENESIS Pharma in 2026.

Incident Types GENESIS Pharma vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for GENESIS Pharma in 2026.

Incident History - GENESIS Pharma (X = Date, Y = Severity)

Loading…

SUBSIDIARY

GENESIS Pharma Subsidiaries

Parent Company

GENESIS Pharma

Pharmaceutical Manufacturing

Website: https://www.genesispharma.com

Company Size: 193

No subsidiary data available for this company.

Loading…

GENESIS Pharma Similar Companies

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

EMS

cb ems.com.br

Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Servier

servier.com

Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Loading…

NEWS

GENESIS Pharma CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 06, 2026 08:00 AM

Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe

MUNICH, January 07, 2026--Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern...

Read Article

December 15, 2025 08:00 AM

GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe

ATHENS, Greece–(BUSINESS WIRE)–. ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY. GENESIS...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-111369

SUMMARY

ClassroomIO through 1.0.0 contains an incorrect authorization vulnerability in the PUT and DELETE /:lessonId lesson routes that allows any course member, including students, to modify lessons. Authenticated students can supply arbitrary lesson ids to change titles and stored HTML content or delete lessons in their course and in other courses and organizations.

Published

Date2026-10-15

Updated

Date2026-10-15

RISK INFORMATION (Score: 7.1)

cvss3

Base Score: 7.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:H/A:L

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:N/VI:H/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

4.2

Exploitability

2.8

REFERENCES

CVE-2026-111368

SUMMARY

ClassroomIO through 1.0.0 contains an insecure direct object reference vulnerability in the Hono API course submission routes that allows course tutors or admins to modify submissions in other courses. Attackers can supply their own course id with another course's submission UUID to PUT or DELETE handlers to overwrite answers, grades, feedback, and grading status or delete submissions.

Published

Date2026-10-15

Updated

Date2026-10-15

RISK INFORMATION (Score: 6.4)

cvss3

Base Score: 6.4

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:L/I:H/A:L

cvss4

Base Score: 6.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:L/UI:N/VC:L/VI:H/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

4.7

Exploitability

1.6

REFERENCES

CVE-2026-111367

SUMMARY

BillionMail through 4.9 contains a hard-coded cryptographic key vulnerability that allows unauthenticated attackers to forge unsubscribe and subscribe-confirm JWTs by computing the key from shipped configuration constants. Attackers can submit forged tokens to /api/unsubscribe, /api/unsubscribe_new, or /api/subscribe/confirm to deactivate any contact or force confirmed subscriptions.

Published

Date2026-10-15

Updated

Date2026-10-15

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:L

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.5

Exploitability

3.9

REFERENCES

CVE-2026-111366

SUMMARY

cool-admin-midway through 8.0.0 contains an authorization bypass vulnerability that allows department-limited admins to manage users outside their departments by supplying arbitrary user ids. Attackers holding sys:user:* permissions can call /admin/sys/user/info, update, or delete to read records, reset passwords and roles, or delete accounts.

Published

Date2026-10-15

Updated

Date2026-10-15

RISK INFORMATION (Score: 7.2)

cvss3

Base Score: 7.2

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 8.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

1.2

REFERENCES

CVE-2026-111365

SUMMARY

cool-admin-midway through 8.0.0 contains an authorization bypass vulnerability that allows non-superadmin admins to read, modify, or delete other admins' roles by supplying arbitrary role ids. Attackers holding ordinary sys:role permissions can call /admin/sys/role/info, update, or delete with another admin's role id to rewrite menu and department grants, changing other users' effective access.

Published

Date2026-10-15

Updated

Date2026-10-15

RISK INFORMATION (Score: 6)

cvss3

Base Score: 6.0

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:L/I:H/A:L

cvss4

Base Score: 7.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:L/VI:H/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

4.7

Exploitability

1.2

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

GENESIS Pharma Vendor Cyber Rating & Cyber Score

GENESIS Pharma A.I CyberSecurity Scoring

GENESIS Pharma CyberSecurity News & History

GENESIS Pharma Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for GENESIS Pharma

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types GENESIS Pharma vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - GENESIS Pharma (X = Date, Y = Severity)

GENESIS Pharma Subsidiaries

Parent Company

GENESIS Pharma

GENESIS Pharma Similar Companies

Zoetis

Novo Nordisk

EMS

Alembic Pharmaceuticals Limited

Servier

Eli Lilly and Company

MACLEODS PHARMACEUTICALS LTD.

Viatris

Lonza

GENESIS Pharma CyberSecurity News

Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe

GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

GENESIS Pharma CyberSecurity News & History

GENESIS Pharma Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for GENESIS Pharma

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types GENESIS Pharma vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - GENESIS Pharma (X = Date, Y = Severity)

GENESIS Pharma Subsidiaries

Parent Company

GENESIS Pharma

GENESIS Pharma Similar Companies

Zoetis

Novo Nordisk

EMS

Alembic Pharmaceuticals Limited

Servier

Eli Lilly and Company

MACLEODS PHARMACEUTICALS LTD.

Viatris

Lonza

GENESIS Pharma CyberSecurity News

Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe

GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo